aid: connectbiopharm
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/connectbiopharm.png
name: Connect Biopharma
description: Connect Biopharma is a clinical-stage biopharmaceutical company headquartered in San
  Diego, California, dedicated to transforming care for patients with inflammatory diseases such as
  asthma and COPD. Its lead drug candidate, rademikibart (CBP-201), is an antibody targeting IL-4Ra
  in Phase 2 clinical development for acute asthma and COPD exacerbations. Surfaced as a portfolio
  company of the venture firm Qiming and added to the API Evangelist network, the company operates in
  the pharmaceutical and biotechnology sector and publishes no public developer portal, API, or
  technical documentation.
url: https://raw.githubusercontent.com/api-evangelist/connectbiopharm/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- qiming
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Biotechnology
- Clinical-Stage
- Inflammatory Diseases
- Respiratory
- Asthma
- COPD
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/connectbiopharm-domain-security.yml
- type: Website
  url: https://www.connectbiopharma.com
- type: PrivacyPolicy
  url: https://www.connectbiopharma.com/privacy-policy
- type: TermsOfService
  url: https://www.connectbiopharma.com/terms-and-conditions
- type: Support
  url: https://www.connectbiopharma.com/contact
- type: Blog
  url: https://www.connectbiopharma.com/news-media
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence